Biography:

James completed his PhD in Melbourne, Australia at the Peter MacCallum Cancer Centre and The University of Melbourne. His PhD was focused on lesser known components of the WNT signalling pathway and characterising their roles in cancer, including therapy resistance. James then joined the Chapman group in 2021 to begin a postdoc developing novel immunotherapies for myeloma.

Research interests:

Immunotherapy has revolutionised the treatment of haematological malignancies including myeloma, a plasma cell malignancy. However, due to the high rate of relapse among patients novel therapies are required. James is developing novel immunotherapies (e.g. CAR-T, CAR-NK and bispecific antibodies) for myeloma that are not only efficacious but have reduced toxicity.